S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
NYSEAMERICAN:AST

Asterias Biotherapeutics (AST) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
99,200 shs
Average Volume
136,653 shs
Market Capitalization
$52.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AST stock logo

About Asterias Biotherapeutics (NYSEAMERICAN:AST) Stock

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Receive AST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AST Stock News Headlines

How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
BrightPath Biotherapeutics Co Ltd (4594)
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
SONN Sonnet BioTherapeutics Holdings, Inc.
Sensei Biotherapeutics Slashes Workforce, Closes R&D Site
Navana CNG Ltd (NAVA)
Asterias Biotherapeutics Inc (AST)
See More Headlines

Receive AST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AST Company Calendar

Last Earnings
3/28/2017
Today
5/30/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:AST
Previous Symbol
NYSEMKT:AST
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$52.32 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Michael H. Mulroy (Age 53)
    CEO, Pres & Director
  • Dr. Edward D. Wirth III (Age 54)
    Chief Medical Officer
  • Dr. Katharine E. Spink (Age 45)
    Consultant
  • Mr. Stephen L. Cartt (Age 56)
    Advisor & Director
  • Mr. Ryan D. Chavez (Age 43)
    CFO & Gen. Counsel













AST Stock - Frequently Asked Questions

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analyst estimates of $2.81 million.

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), Amarin (AMRN), Anavex Life Sciences (AVXL) and Freeport-McMoRan (FCX).

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How do I buy shares of Asterias Biotherapeutics?

Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $0.94.

How much money does Asterias Biotherapeutics make?

Asterias Biotherapeutics (NYSEAMERICAN:AST) has a market capitalization of $52.32 million.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The official website for the company is asteriasbiotherapeutics.com. The biotechnology company can be reached via phone at +1-510-4563805.

This page (NYSEAMERICAN:AST) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -